X

Download SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER PowerPoint Presentation


Login   OR  Register
X

Share page



  Preview

               
Home / Health & Wellness / Health & Wellness Presentations / SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER PowerPoint Presentation

SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER PowerPoint Presentation

onlinesearch By : onlinesearch

On : Feb 24, 2014

In : Health & Wellness

Embed :
630
views

0
downloads
Login / Signup - with account for


  • → Make favorite
  • → Flag as inappropriate
  • → Download Presentation
  • → Share Presentation
  • Slide 1 - SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER?Mark H. Stoler, MD
  • Slide 2 - Estimated Annual Burden of HPV-Related Diagnoses in the United States 1 million new cases of genital warts3 1.4 million new cases of low-grade cervical dysplasia (CIN 1)2 330,000 new cases of high-grade cervical dysplasia (CIN 2/3)2 9,710 new cases of cervical cancer1 1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society; 2006:4. 2. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127:946–949. 3. Fleischer AB, Parrish CA, Glenn R, Feldman SR. Condylomata acuminata (genital warts):Patient demographics and treating physicians. Sex Transm Dis. 2001;28:643–647. 3,700 deaths estimated in 20061 CIN = cervical intraepithelial neoplasia. CIN = cervical intraepithelial neoplasia.
  • Slide 3 - ppt slide no 3 content not found
  • Slide 4 - ppt slide no 4 content not found
  • Slide 5 - ppt slide no 5 content not found
  • Slide 6 - 6 20% Oropharyngeal ≥95% Cervical* 90%** Nonmelanoma skin/cutaneous squamous cell >70% Anal 50% Penile >50% Vulvar* 50% Vaginal* % Associated with Certain HPV Types Cancer HPV and Cancer1 *Includes cancer and intraepithelial neoplasia ** Immunocompromised patients 1. Gonzalez Intxaurraga MA, Stankovic R, Sorli R, Trevisan G. Acta Dermatovenerol. 2002;11:1–8.
  • Slide 7 - 7 1 Efficacy Objective of Clinical Program for GARDASIL® – Demonstrate Prevention of HPV 16/18-CIN 2/3 and AIS Natural History of HPV Infection 0 to 1 Year 0 to 3 Years Up to 20 Years InitialHPV Infection CIN 1 Cleared HPV Infection Definitive Efficacy Cervical Cancer CIN 2/3 or AIS ContinuingInfection
  • Slide 8 - 8 IN2/3 is Noninvasive cancer Clear precursor relationship HPV types the same Invasive cancer develops from IN3
  • Slide 9 - GARDASIL: The First Cervical Cancer Vaccine in the United States Quadrivalent HPV 6/11/16/18 L1 virus-like particle (VLP) vaccine VLPs are produced in Saccharomyces cerevisiae. The L1 proteins self-assemble into VLPs. Purified VLPs are adsorbed on aluminum-containing adjuvant. The adjuvant is amorphous aluminum hydroxyphosphate sulfate (225 μg per dose). Each 0.5-mL dose contains HPV Types 6/11/16/18 (20/40/40/20 μg L1 protein, respectively).
  • Slide 10 - Prophylactic Efficacy of GARDASIL CIN & AIS Per-Protocol Population (Protocols 007, 013, and 015) Mean Follow-Up - 44 months
  • Slide 11 - Prophylactic Efficacy of GARDASIL® External Genital LesionsPer-Protocol Population (Protocols 007, 013, and 015) Mean Follow-Up - 44 months * Subjects are counted only once per row, but may be in more than one row
  • Slide 12 - 27% of subjects had evidence of prior exposure to or ongoing infection with at least 1 of the 4 vaccine HPV types. Subjects Exposed to Any Vaccine HPV Type at Enrollment 73% of subjects were naïve to all 4 vaccine HPV types. Among subjects who were positive to a vaccine HPV type, most were positive to only 1 type. Exclusion criteria: 6 or more sexual partners Baseline HPV Status Efficacy Studies—Combined Population Naïve to all 4 types Positive to 1 type Positive to 2 types Positive to 3 types Positive to 4 types 93% of subjects were naïve to ≥3 vaccine HPV types (6, 11, 16, or 18) at enrollment. 1.2% 0.1% 6% 73% Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20651717(4)-GRD.
  • Slide 13 - Efficacy of GARDASIL in Subjects Who Were Positive to ≥1 Vaccine HPV Type at Day 1 CIN = cervical intraepithelial neoplasia; VIN = vulvar intraepithelial neoplasia; VaIN = vaginal intraepithelial neoplasia *Among subjects who were positive to ≥ 1 vaccine HPV type, efficacy against HPV types for which they were naïve at Day 1. n = Number of subjects in the given population with at least 1 follow-up visit following 30 days after Day 1. Subjects are counted once in each applicable end-point category. A subject may appear in more than 1 category. Ph III–FUTURE I (P013) and FUTURE II (P015) Case-counting Postdose 1 Individuals with current or past infection with 1 vaccine-related HPV types prior to vaccination were protected from disease caused by the remaining vaccine HPV types for which they were naïve at Day 1. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20651717(5)-GRD.
  • Slide 14 - Impact of GARDASIL Against HPV 6/11/16/18-Related CIN (Any Grade) Based on HPV Status at Day 1; Combined Analysis Seropositive and PCR-positive at baseline GARDASIL is a prophylactic vaccine. There is no clear evidence of protection from disease caused by HPV types for which subjects were seropositive and/or PCR positive at baseline. AIS = adenocarcinoma in situ. CIN = cervical intraepithelial neoplasia. Data available on request from Merck & Co., Inc., Professional Services-DAP, WP1-27, PO Box 4, West Point, PA 19486-0004. Please specify information package 20651717(6)-GRD.
  • Slide 15 - Overall Conclusions for GARDASIL Highly effective in preventing cervical cancer, CIN 2/3, AIS, and other anogenital diseases including genital warts caused by HPV 6, 11, 16, and 18 in 16- to 26-year-old women naïve to the relevant HPV types Individuals with current or past infection with 1 vaccine-related HPV types prior to vaccination were protected from disease caused by the remaining vaccine HPV types Successful immunogenicity bridge between female adolescents and young adult women Antibody response in 9- to 15-year-old females is higher, compared with response observed in young adult women (16–26 years old) Duration of efficacy is demonstrated between 2 and 4 years Favorable tolerability profile AIS = adenocarcinoma in situ. CIN = cervical intraepithelial neoplasia.
  • Slide 16 - Summary of US Vaccine Recommendations aACIP = Advisory Committee on Immunization Practices. bACOG = American College of Obstetricians and Gynecologists. cAAFP = American Academy of Family Practitioners. dACP = American College of Physicians. eAAP = American Academy of Pediatrics. 1.Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2007;56(RR-2):1-24. 2. American College of Obstetricians and Gynecologists (ACOG). Obstet Gynecol. 2006;108:699–705. 3. Advisory Committee on Immunization Practices. Ann Intern Med. 2007;147(10):725-729. 4. Committee on Infectious Diseases. Pediatrics. 2007; 120(3);666-668.
  • Slide 17 - Important Information About GARDASIL GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by human papillomavirus (HPV) Types 6, 11, 16, and 18. GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine. GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care. GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]
  • Slide 18 - Important Information About GARDASIL (cont) Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not recommended for use in pregnant women. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; CIN, VIN, or VaIN.a GARDASIL has not been shown to protect against diseases due to non-vaccine HPVb types. The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness. In addition, common postmarketing reports include vomiting and syncope. aCIN = cervical intraepithelial neoplasia; VIN = vulvar intraepithelial neoplasia; VaIN = vaginal intraepithelial neoplasia. bHPV = human papillomavirus. GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Description : Available SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags : SHOULD I VACCINATE MY CHILD AGAINST CERVICAL CANCER

Shortcode : Get Shareable link